| |
No Supplement (N = 511)
|
MVI
|
D
|
D + MVI
|
P value
|
|---|
|
(N = 322)
|
(N = 42)
|
(N = 68)
|
|---|
| |
Mean (SD)
|
F test
|
|
Age in years
|
60.1 (9.7)
|
61.8 (8.6)*
|
65.3 (6.4)*
|
65.5 (7.7)*
|
< 0.0001
|
|
Age at PD Dx
|
58.5 (9.7)
|
60.2 (8.7)*
|
63.9 (6.6)*
|
64.1 (7.7)*
|
< 0.0001
|
|
Yrs since Dx
|
1.6 (1.1)
|
1.7 (1.2)
|
1.3 (1.0)
|
1.4 (0.8)
|
0.07
|
|
Years since Dx to D-treatment
|
1.1 (1.1)
|
1.3 (1.2)
|
0.9 (1.0)
|
1.0 (0.8)
|
0.08
|
|
UPDRS total
|
25.1 (10.3)
|
25.4 (10.3)
|
25.1 (11.4)
|
24.5 (9.8)
|
0.92
|
|
UPDRS mental
|
1.2 (1.3)
|
1.2 (1.3)
|
1.4 (1.4)
|
1.2 (1.3)
|
0.85
|
|
UPDRS ADL
|
6.8 (3.7)
|
6.8 (3.6)
|
6.2 (3.9)
|
6.4 (3.4)
|
0.66
|
|
PDQ 39 summary
|
12.9 (10.4)
|
11.5 (8.7)
|
12.5 (9.6)
|
10.5 (8.3)
|
0.08
|
|
SCOPA COG
|
30.4 (5.1)
|
30.4 (5.2)
|
30.9 (4.6)
|
31.1 (5.0)
|
0.71
|
|
SDMT
|
45.1 (11.1)
|
44.4 (10.9)
|
45.2 (11.4)
|
45.9 (11.4)
|
0.71
|
|
Total daily LED
|
374.9 (224.9)
|
371.3 (232.8)
|
390.0 (208.0)
|
367.4 (355.4)
|
0.96
|
| |
Frequency (%)
|
X2testa
|
|
Female %
|
144 (28.2%)
|
94 (29.2%)
|
27 (64.3%)
|
38 (55.9%)
|
< 0.0001
|
|
Non-Hispanic white
|
448 (87.7%)
|
303 (94.1%)
|
41 (97.6%)
|
66 (97.1%)
|
0.001
|
|
Education > 17 yearsa
|
149 (29.2%)
|
118 (36.7%)
|
16 (38.1%)
|
18 (26.5%)
|
0.08
|
- Abbreviations: PD Parkinson’s disease, Dx diagnosis, yrs years, D-treatment dopaminergic treatment (dopamine agonist or levodopa), UPDRS Unified Parkinson’s Disease Rating Scale, ADL activities of daily living, PDQ Parkinson’s disease questionnaire, SCOPA COG Scales for outcomes of Parkinson’s disease-Cognition, SDMT symbol digit modalities test, LED levodopa equivalent dose
- *p < .05 compared to NoSupp, according to pairwise comparisons Hochberg method
- aX2 test was calculated by Fisher’s exact test
